Istvan Wollak, MD
Pulmonary Disease · Southaven, MSNPI 1619919305
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,460 of the $4,861 with a category attached, or 71.2%. It is spread thinly across 31 manufacturers, the largest accounting for just 23.4%. Reporting peaked in 2023 at $1,665 and has fallen 56.8% since, to $718 in 2025. That places this record below the midpoint for pulmonary disease clinicians in MS, where the typical reported total is $4,861.
Across 210 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- Actelion Pharmaceuticals US, Inc.$983
- GSK$571
- Insmed, Inc.$472
- AstraZeneca$268
- Harmony Biosciences LLC$216
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$1002%
- Travel & lodging$1,07622%
- Food & beverage$3,46071%
- Education$2255%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $1,135 |
| Actelion Pharmaceuticals US, Inc. | 58 | $983 |
| GSK | 35 | $571 |
| Insmed, Inc. | 23 | $472 |
| AstraZeneca(2 entities) | 13 | $268 |
| Harmony Biosciences LLC | 7 | $216 |
| Genentech USA, Inc. | 8 | $132 |
| United Therapeutics Corporation | 3 | $123 |
| Jazz Pharmaceuticals Inc. | 5 | $87 |
| Novartis | 5 | $76 |
| Grifols USA, LLC | 5 | $73 |
| Merck | 4 | $73 |
| Portola Pharmaceuticals, LLC | 3 | $72 |
| Electromed, Inc. | 6 | $70 |
| Boehringer Ingelheim | 4 | $70 |
| Sanofi | 3 | $62 |
| Bayer | 3 | $56 |
| La Jolla Pharmaceutical Company | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Amgen | 1 | $27 |
| Ambu Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Fisher & Paykel Healthcare Inc | 1 | $18 |
| Pfizer | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Boston Scientific | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,051
How this compares
$4,861 in reported general payments places this provider in the 50th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 77 | $957,710 |
| OfevNintedanib Esylate | 33 | $432,274 |
| AdempasRiociguat | 28 | $393,122 |
| Fasenra PenBenralizumab | 31 | $176,110 |
| NucalaMepolizumab | 37 | $135,810 |
| XolairOmalizumab | 38 | $122,021 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $85,763 |
| Dupixent SyringeDupilumab | 15 | $58,760 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $31,701 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $15,474 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $10,160 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $6,975 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,924 |
| Sildenafil Citrate | 33 | $3,688 |
| Pulmicort FlexhalerBudesonide | 12 | $3,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $983 | $957,71077 claims |
| Boehringer IngelheimOfev, Stiolto Respimat | $70 | $439,24948 claims |
| BayerAdempas | $56 | $393,12228 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta | $571 | $263,433211 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $268 | $22,58939 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Southaven
- Yadana KyawSouthaven$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$276K
- Michal SenitkoJackson$185K
- Cameron HuxfordStarkville$155K
- L AldredHattiesburg$76K
- Andrew WilhelmJackson$51K
- Raymond PortisJackson$39K
- Jaime UngoTupelo$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.